| Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs | Frank Vinluan | 09/28/20 | Boston |
| Acadia Halts Work on Depression Drug After Late-Stage Trial Failure | Sarah de Crescenzo | 07/21/20 | San Diego |
| Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs | Frank Vinluan | 05/04/20 | Boston |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug | Frank Vinluan | 04/07/20 | Boston |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned | Frank Vinluan | 12/16/19 | New York |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60% | Frank Vinluan | 12/05/19 | Boston |
| The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It? | Alex Lash | 10/10/19 | National |
| Can AI Tools, $76M Lead BlackThorn to Targeted Psych Drugs? | Ben Fidler | 06/13/19 | San Francisco |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More | Alex Lash | 03/08/19 | National |
| Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More | Ben Fidler | 02/08/19 | National |
| FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data | Frank Vinluan | 02/01/19 | Boston |
| Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges | Corie Lok | 01/07/19 | Boston |
| Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure | Frank Vinluan | 12/10/18 | Boston |
| Cadent Pulls In $40M for Phase 2 Tests of Movement Disorder Drug | Frank Vinluan | 11/15/18 | Boston |
| Bio Roundup: Depression Drug Dashed, Peek at ASH, CRISPR Worry & More | Alex Lash | 11/02/18 | National |
| Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No | Ben Fidler | 11/01/18 | Boston |
| FDA Blasts Data, Trial Design For Alkermes Depression Drug | Ben Fidler | 10/30/18 | Boston |
| Zafgen Exec Thomas Hughes Resigns to Take CEO Job at Navitor | Frank Vinluan | 08/02/18 | Boston |
| Akili Grabs $55M, Seeking FDA Approval of First Video Game Therapy | Jeff Bauter Engel | 05/09/18 | Boston |
| Will New Study Cut Guesswork for Depression Medicine Prescriptions? | Alex Lash | 05/07/18 | National |
| San Antonio Startup Adds Funding to Treat PTSD with Magnetic Field | David Holley | 05/03/18 | Texas |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| Alkermes Depression Drug Review Goes Ahead After FDA About-Face | Corie Lok | 04/16/18 | Boston |
| Bio Roundup: Ex-Kiters Say Allo, NASH Cash & Data, Alkermes No & More | Alex Lash | 04/06/18 | National |
| Former National Mental Health Chief Thomas Insel Leaving Verily | Alex Lash | 05/09/17 | San Francisco |
| Tetra Discovery Raises $10M Series A, Advances Alzheimer’s Drug | Sarah Schmid Stevenson | 11/30/16 | Detroit Ann Arbor |
